<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02855281</url>
  </required_header>
  <id_info>
    <org_study_id>WI_16-233</org_study_id>
    <nct_id>NCT02855281</nct_id>
  </id_info>
  <brief_title>Sensitivity of PDL-1-analysis From Pleural Effusion in Non-small Cell Lung Cancer</brief_title>
  <official_title>Sensitivity of PDL-1-analysis From Pleural Effusion in Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wissenschaftliches Institut Bethanien e.V</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Pathology, University Clinic Düsseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wissenschaftliches Institut Bethanien e.V</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective diagnostic pilot study to create hypotheses regarding&#xD;
      immunocytochemistry (ICC) PD-L1 analysis of pleural effusions in NSCLC patients as compared&#xD;
      to the reference standard of PD-L1 immunohistochemistry (IHC). This comparison will be done&#xD;
      to assess sensitivity and specificity of PD-L1 detection by ICC in pleural effusions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PD-L1 Prevalence IHC</measure>
    <time_frame>At baseline</time_frame>
    <description>Number/prevalence of PD-L1-positive patients according to immunohistochemistry (IHC) of pleural biopsy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PD-L1 Prevalence ICC</measure>
    <time_frame>At baseline</time_frame>
    <description>Number/prevalence of PD-L1-positive patients according to immunocytochemistry (ICC) of pleural aspirate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PD-L1 Detection in Pleural Effusion Based on All Cases With Successful PD-L1 Analysis</measure>
    <time_frame>At baseline</time_frame>
    <description>Based on all cases where PD-L1 analysis was indicated and sucessful (i.e. giving definite results), the immunocytochemistry analysis of PE was compared with the immunohistochemistry analysis of pleural tissue.Two different alternatives were calculated:&#xD;
PD-L1 expression with a TPS ≥50% was defined as PD-L1-positive.&#xD;
PD-L1 expression with a TPS ≥1% was defined as PD-L1-positive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PD-L1 Detection in Pleural Effusion Based on All Cases With Indication for PD-L1 Analysis</measure>
    <time_frame>At baseline</time_frame>
    <description>Based on all cases where PD-L1 analysis was indicated, the immunocytochemistry analysis of PE was compared with the immunohistochemistry analysis of pleural tissue.Two different alternatives were calculated:&#xD;
PD-L1 expression with a TPS ≥50% was defined as PD-L1-positive.&#xD;
PD-L1 expression with a TPS ≥1% was defined as PD-L1-positive. In both instances, cases where PD-L1 analysis could not be performed were defined as negative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Cell Detection in Pleural Effusion</measure>
    <time_frame>At baseline</time_frame>
    <description>Comparing the immunocytochemistry (ICC) analysis of pleural effusion concerning the detection of malignant tumor cells as compared to the immunohistochemistry analysis of pleural tissue. Seven cases of ICC analysis with inconclusive results were defined as negative.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>NSCLC with pleural effusion</arm_group_label>
    <description>The population for selection of potential study participants is comprised of clinical routine patients presenting with (suspected malignant) pleural effusion. These patients must have an indication for pleural puncture. The cause and nature of the pleural effusion at this time point will be unknown in many cases. To establish this, further diagnostic procedures are required. Only patients with confirmed diagnosis of non-small cell lung cancer will be included in the data analysis.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The population for selection of potential study participants is comprised of clinical&#xD;
        routine patients presenting with (suspected malignant) pleural effusion. These patients&#xD;
        must have an indication for pleural puncture. The cause and nature of the pleural effusion&#xD;
        at this time point will be unknown in many cases. To establish this, further diagnostic&#xD;
        procedures are required. Only patients with confirmed diagnosis of non-small cell lung&#xD;
        cancer will be included in the data analysis.&#xD;
&#xD;
        A patient in whom suspicion of pleural manifestation of lung cancer is not confirmed, will&#xD;
        be considered a screening failure and thus excluded from the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of malignant pleural effusion with indication for pleural puncture and&#xD;
             thoracoscopy&#xD;
&#xD;
          -  Confirmed diagnosis of non-small cell lung cancer according to ERS guidelines&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy and/or lactation&#xD;
&#xD;
          -  Acute and life-threatening illness (instable angina pectoris, acute pulmonary arterial&#xD;
             embolism, myocardial infarction, etc.)&#xD;
&#xD;
          -  Any contraindication to undergo thoracoscopy (e.g. anticoagulation therapy which&#xD;
             cannot be discontinued for the procedure)&#xD;
&#xD;
          -  Any medical, psychological or other condition impairing the patient's ability to&#xD;
             provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Winfried J Randerath, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wissenschaftliches Institut Bethanien e.V</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wissenschaftliches Institut Bethanien e. V.</name>
      <address>
        <city>Solingen</city>
        <state>NRW</state>
        <zip>42699</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2016</study_first_posted>
  <results_first_submitted>February 12, 2021</results_first_submitted>
  <results_first_submitted_qc>February 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2021</results_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 4, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT02855281/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Clinical routine patients presenting with (suspected malignant) pleural effusion and indication for pleural puncture were considered for enrollment. Patients with confirmed malignancy of pleural effusion were actually enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Malignant Pleural Effusion</title>
          <description>Patients with confirmed malignant pleural effusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>patients with confirmed diagnosis of non-small cell lung cancer</population>
      <group_list>
        <group group_id="B1">
          <title>Malignant Pleural Effusion</title>
          <description>patients with confirmed malignant pleural effusion</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.5" lower_limit="62.8" upper_limit="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.7" lower_limit="23.2" upper_limit="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>smoking status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histology Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>NSCLC - Adeno carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NSCLC - Squamous cell carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NSCLC - large-cell neuroendocrine carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>SCLC</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>SCLC + Adeno carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Hodgkin Lymphoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Sarcomatoid Mesothelioma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ambiguous histology</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer Stage (UICC 8th ed.)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>IA2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IB</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IIB</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IIIA</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IIIB</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IVA</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IVB</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>III-IV (IMIG classification)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PD-L1 Prevalence IHC</title>
        <description>Number/prevalence of PD-L1-positive patients according to immunohistochemistry (IHC) of pleural biopsy.</description>
        <time_frame>At baseline</time_frame>
        <population>Thoracoscopy was performed in all fifty patients. PD-L1 analysis of pleural tissue was indicated in all samples with evidence of tumor cells (n=40), excluding cases with small-cell lung cancer (n=2). Mainly due to insufficient sample material (low tumor cell count) (n=3), PD-L1 analysis could actually be performed in 35 pleural tissue cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Number of PD-L1-positive Samples in IHC</title>
            <description>For the assessment of potentially therapy-relevant PD-L1 expression levels, two different threshold levels of PD-L1 expression were considered as per the differing approval status (TPS ≥50% and TPS≥1%). Regarding detection of malignancy and PD-L1-positivity, results were defined as negative where the tests were not feasible or in case of inconclusive findings.</description>
          </group>
        </group_list>
        <measure>
          <title>PD-L1 Prevalence IHC</title>
          <description>Number/prevalence of PD-L1-positive patients according to immunohistochemistry (IHC) of pleural biopsy.</description>
          <population>Thoracoscopy was performed in all fifty patients. PD-L1 analysis of pleural tissue was indicated in all samples with evidence of tumor cells (n=40), excluding cases with small-cell lung cancer (n=2). Mainly due to insufficient sample material (low tumor cell count) (n=3), PD-L1 analysis could actually be performed in 35 pleural tissue cases.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PD-L1 expression with a TPS ≥ 1% was defined as PD-L1-positive</title>
              <category_list>
                <category>
                  <title>PD-L1 positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PD-L1 negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PD-L1 expression with a TPS ≥ 50% was defined as PD-L1-positive</title>
              <category_list>
                <category>
                  <title>PD-L1 positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PD-L1 negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PD-L1 Prevalence ICC</title>
        <description>Number/prevalence of PD-L1-positive patients according to immunocytochemistry (ICC) of pleural aspirate</description>
        <time_frame>At baseline</time_frame>
        <population>Pleural puncture was performed in all fifty patients. PD-L1 analysis of pleural effusion was indicated in all samples with evidence of tumor cells (n=36), excluding cases with small-cell lung cancer (n=3). Mainly due to insufficient sample material (low tumor cell count) (n=7) or technical issue (n=1), PD-L1 analysis could actually be performed in 25 pleural effusion cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Number of PD-L1-positive Samples in ICC</title>
            <description>For the assessment of potentially therapy-relevant PD-L1 expression levels, two different threshold levels of PD-L1 expression were considered as per the differing approval status (TPS ≥50% and TPS≥1%). Regarding detection of malignancy and PD-L1-positivity, results were defined as negative where the tests were not feasible or in case of inconclusive findings.</description>
          </group>
        </group_list>
        <measure>
          <title>PD-L1 Prevalence ICC</title>
          <description>Number/prevalence of PD-L1-positive patients according to immunocytochemistry (ICC) of pleural aspirate</description>
          <population>Pleural puncture was performed in all fifty patients. PD-L1 analysis of pleural effusion was indicated in all samples with evidence of tumor cells (n=36), excluding cases with small-cell lung cancer (n=3). Mainly due to insufficient sample material (low tumor cell count) (n=7) or technical issue (n=1), PD-L1 analysis could actually be performed in 25 pleural effusion cases.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PD-L1 expression with a TPS ≥ 1% was defined as PD-L1-positive</title>
              <category_list>
                <category>
                  <title>PD-L1 positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PD-L1 negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PD-L1 expression with a TPS ≥ 50% was defined as PD-L1-positive</title>
              <category_list>
                <category>
                  <title>PD-L1 positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PD-L1 negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PD-L1 Detection in Pleural Effusion Based on All Cases With Successful PD-L1 Analysis</title>
        <description>Based on all cases where PD-L1 analysis was indicated and sucessful (i.e. giving definite results), the immunocytochemistry analysis of PE was compared with the immunohistochemistry analysis of pleural tissue.Two different alternatives were calculated:&#xD;
PD-L1 expression with a TPS ≥50% was defined as PD-L1-positive.&#xD;
PD-L1 expression with a TPS ≥1% was defined as PD-L1-positive.</description>
        <time_frame>At baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sensitivity and Specificity of PD-L1 Detection in Pleural Effusion (TPS ≥50%)</title>
            <description>Sensitivity and specificity of PD-L1 detection in pleural effusion. PD-L1 expression with a TPS ≥50% was defined as PD-L1-positive.</description>
          </group>
          <group group_id="O2">
            <title>Sensitivity and Specificity of PD-L1 Detection in Pleural Effusion (TPS ≥1%)</title>
            <description>Sensitivity and specificity of PD-L1 detection in pleural effusion. PD-L1 expression with a TPS ≥ 1% was defined as PD-L1 positive.</description>
          </group>
        </group_list>
        <measure>
          <title>PD-L1 Detection in Pleural Effusion Based on All Cases With Successful PD-L1 Analysis</title>
          <description>Based on all cases where PD-L1 analysis was indicated and sucessful (i.e. giving definite results), the immunocytochemistry analysis of PE was compared with the immunohistochemistry analysis of pleural tissue.Two different alternatives were calculated:&#xD;
PD-L1 expression with a TPS ≥50% was defined as PD-L1-positive.&#xD;
PD-L1 expression with a TPS ≥1% was defined as PD-L1-positive.</description>
          <units>percent</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="46" upper_limit="100"/>
                    <measurement group_id="O2" value="86" lower_limit="56" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="36" upper_limit="84"/>
                    <measurement group_id="O2" value="43" lower_limit="12" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>positive predictive value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="18" upper_limit="75"/>
                    <measurement group_id="O2" value="75" lower_limit="47" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>negative predictive value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="66" upper_limit="100"/>
                    <measurement group_id="O2" value="60" lower_limit="17" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD-L1 Detection in Pleural Effusion Based on All Cases With Indication for PD-L1 Analysis</title>
        <description>Based on all cases where PD-L1 analysis was indicated, the immunocytochemistry analysis of PE was compared with the immunohistochemistry analysis of pleural tissue.Two different alternatives were calculated:&#xD;
PD-L1 expression with a TPS ≥50% was defined as PD-L1-positive.&#xD;
PD-L1 expression with a TPS ≥1% was defined as PD-L1-positive. In both instances, cases where PD-L1 analysis could not be performed were defined as negative.</description>
        <time_frame>At baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sensitivity and Specificity of PD-L1 Detection in Pleural Effusion (TPS ≥50%)</title>
            <description>Sensitivity and specificity of PD-L1 detection in pleural effusion. PD-L1 expression with a TPS ≥50% was defined as PD-L1-positive.</description>
          </group>
          <group group_id="O2">
            <title>Sensitivity and Specificity of PD-L1 Detection in Pleural Effusion (TPS ≥1%)</title>
            <description>Sensitivity and specificity of PD-L1 detection in pleural effusion. PD-L1 expression with a TPS ≥ 1% was defined as PD-L1 positive.</description>
          </group>
        </group_list>
        <measure>
          <title>PD-L1 Detection in Pleural Effusion Based on All Cases With Indication for PD-L1 Analysis</title>
          <description>Based on all cases where PD-L1 analysis was indicated, the immunocytochemistry analysis of PE was compared with the immunohistochemistry analysis of pleural tissue.Two different alternatives were calculated:&#xD;
PD-L1 expression with a TPS ≥50% was defined as PD-L1-positive.&#xD;
PD-L1 expression with a TPS ≥1% was defined as PD-L1-positive. In both instances, cases where PD-L1 analysis could not be performed were defined as negative.</description>
          <units>percent</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="30" upper_limit="95"/>
                    <measurement group_id="O2" value="71" lower_limit="44" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="49" upper_limit="87"/>
                    <measurement group_id="O2" value="64" lower_limit="36" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>positive predictive value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="16" upper_limit="71"/>
                    <measurement group_id="O2" value="71" lower_limit="44" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>negative predictive value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="65" upper_limit="98"/>
                    <measurement group_id="O2" value="64" lower_limit="36" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Cell Detection in Pleural Effusion</title>
        <description>Comparing the immunocytochemistry (ICC) analysis of pleural effusion concerning the detection of malignant tumor cells as compared to the immunohistochemistry analysis of pleural tissue. Seven cases of ICC analysis with inconclusive results were defined as negative.</description>
        <time_frame>At baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sensitivity and Specificity of Tumor Cell Detection</title>
            <description>Sensitivity and specificity of tumor cell detection in pleural effusion. Seven cases of ICC analysis with inconclusive results defined as negative.</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Cell Detection in Pleural Effusion</title>
          <description>Comparing the immunocytochemistry (ICC) analysis of pleural effusion concerning the detection of malignant tumor cells as compared to the immunohistochemistry analysis of pleural tissue. Seven cases of ICC analysis with inconclusive results were defined as negative.</description>
          <units>percent</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="67" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="35" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>positive predictive value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="76" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>negative predictive value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="24" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NSCLC With Pleural Effusion</title>
          <description>The population for selection of potential study participants is comprised of clinical routine patients presenting with (suspected malignant) pleural effusion. These patients must have an indication for pleural puncture. The cause and nature of the pleural effusion at this time point will be unknown in many cases. To establish this, further diagnostic procedures are required. Only patients with confirmed diagnosis of non-small cell lung cancer will be included in the data analysis.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The fact that the PE did not always yield enough material for a comprehensive immunocytochemistry evaluation including PD-L1 analysis, constitutes an important limitation, in part leading to inconclusive results regarding malignancy. This may be due to a low rate of cells scaling off from the pleural lesion and/or a low rate of migration of tumor cells into the pleural fluid.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Lars Hagmeyer</name_or_title>
      <organization>Hospital Bethanien Solingen, Clinic of Pneumology and Allergology, Center for Sleep Medicine and Respiratory Care, Solingen, Germany</organization>
      <phone>0212636004</phone>
      <email>institut@klinik-bethanien.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

